Looking to know more about the role of the right ventricle in the pathophysiology of tricuspid regurgitation? Don’t miss this video!

You’ll learn how to assess RV function and morphology with advanced imaging, uncover key parameters that predict outcomes, understand how RV remodeling impacts procedural success, and...

Curious about managing multivalve disease in the absence of robust clinical evidence? This video is a must-watch!

You'll explore the latest strategies for assessing and treating this condition (including advanced multimodality investigations like echocardiography, magnetic resonance and cardiac catheterisation), and learn how to evaluate cardiopulmonary interactions and...

Explore the latest advancements in aortic valve research during this featured session, showcasing selected abstracts from the upcoming PCR London Valves 2024 conference. Delve into topics ranging from the long-term outcomes of bailout valve-in-valve TAVI, the performance of the Navitor THV in bicuspid aortic valves, novel...

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

At TCT Connect 2020, Late-Breaking Trial Session IV, the primary results of the OPTIMIZE IDE were presented by Dean J. Kereiakes. Daniele Giacoppo provides a summary of the trial.

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.